This article is a follow up to the previous article of a case study where a patient on Terzepatide (Mounjaro) which falls in the same class of medicines as Ozempic and Wegovy to treat diabetes. In that article, a patient on Mounjaro to treat diabetes who also had male pattern balding showed positive hair growth after using it. This was a single patient case study.
In 2023, the FDA flagged hair loss as a potential adverse effect of Ozempic and Wegovy. This year, evaluation of case reports from 2022 to 2023 were carried out to analyse adverse reports of these medication by a group of researchers. 84% of alopecia adverse reports were made by patients and 16% by healthcare professionals.
The researchers found 199 adverse reports of hair loss for Ozempic and 179 for Mounjaro.
This study clearly highlights the need to investigate this association further. More importantly, it shows that one single case study where one patient had good hair growth should not be taken as the norm to start using these GLP-1 agonists to treat hair loss.